Evidence map›Paper›PMID 30911864›Full record

SynthesisDigestive diseases and sciences2019

Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses.

Patrick Snyder, Kerry Dunbar, Daisha J Cipher, Rhonda F Souza, Stuart Jon Spechler, Vani J A Konda

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Guideline
  3. Article
  4. Review
  5. Review
  6. Review
  7. Improving esophageal cancer screening across the globe: Translating knowledge into action.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Unmet needs in Barret's esophagus diagnosis and treatment: a narrative review.Translational gastroenterology and hepatology · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Patrick SnyderDivision of Gastroenterology, Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX, 75246, USA.
Kerry DunbarEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Daisha J CipherCollege of Nursing and Health Innovation, University of Texas at Arlington, 701 S. Nedderman Drive, Mailbox 19407, Arlington, TX, 76019, USA.
Rhonda F SouzaDivision of Gastroenterology, Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX, 75246, USA.
Stuart Jon SpechlerDivision of Gastroenterology, Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX, 75246, USA.
Vani J A KondaDivision of Gastroenterology, Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX, 75246, USA. vanikondaMD@gmail.com.
Baylor Medical Center at Garland · USBaylor University Medical Center · USThe University of Texas at Arlington · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk stratification of patients with Barrett's esophagus (BE) presently relies on the histopathologic grade of dysplasia found in esophageal biopsies, which is limited by sampling error and inter-pathologist variability. p53 immunostaining of BE biopsies has shown promise as an adjunct tool but is not recommended by American gastroenterology societies, who cite insufficient evidence of its prognostic value. We have conducted a systematic review and meta-analyses to clarify this value. We searched for studies that: (1) used immunohistochemistry to assess p53 expression in esophageal biopsies of BE patients and (2) reported subsequent neoplastic progression. We performed separate meta-analyses of case-control studies and cohort studies. We identified 14 relevant reports describing 8 case-control studies comprising 1435 patients and 7 cohort studies comprising 582 patients. In the case-control study meta-analysis of the risk of neoplasia with aberrant p53 expression, the fixed- and random-effect estimates of average effect size with aberrant p53 expression were OR 3.84, p < .001 (95% CI 2.79-5.27) and OR 5.95, p < .001 (95% CI 2.68-13.22), respectively. In the cohort study meta-analysis, the fixed- and random-effect estimates of average effect size were RR = 17.31, p < .001 (95% CI 9.35-32.08) and RR = 14.25, p < .001 (95% CI 6.76-30.02), respectively. Separate meta-analyses of case-control and cohort studies of BE patients who had baseline biopsies with p53 immunostaining revealed consistent, strong, and significant associations between aberrant p53 immunostaining and progression to high-grade dysplasia or esophageal adenocarcinoma. These findings support the use of p53 immunostaining as an adjunct to routine clinical diagnosis for dysplasia in BE patients.

Indexed as

AdenocarcinomaBarrett EsophagusBiomarkers, TumorCase-Control StudiesDisease ProgressionEsophageal NeoplasmsHumansPredictive Value of TestsProspective StudiesRetrospective StudiesStaining and LabelingTumor Suppressor Protein p53Biomarkers, TumorTumor Suppressor Protein p53Barrett’s esophagusBiomarkerEsophageal adenocarcinomaImmunohistochemistryp53

Identifiers

PMID30911864
OpenAlexW2922869362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.